Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.55 |
| ▸ | CDC7 | O00311 | 1/20 | 0.48 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | XBP1 | P17861 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | GRM6 | O15303 | 1/20 | 0.45 |
| ▸ | GUSB | P08236 | 1/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7216561 | 0.83 | ADORA3 (0.60) | CSF1RTSHRHSD17B10USP2MAPK1 | |
| SCHEMBL4466647 | 0.81 | ADORA3 (0.52) | CSF1RCDC7DBF4GABRA2GABRB2 | |
| SCHEMBL4465818 | 0.80 | CDC7 (0.50) | CSF1RCDC7DBF4GABRA2GABRB2 | |
| SCHEMBL8026733 | 0.76 | SIRT2 (0.56) | CSF1RGABRA2GABRB2TSHRHSD17B10 | |
| SCHEMBL29889974 | 0.75 | NPY5R (0.50) | TSHRHSD17B10MAPK1MAPTALDH1A1 | |
| SCHEMBL2943488 | 0.75 | NPY5R (0.50) | TSHRHSD17B10MAPK1MAPTALDH1A1 | |
| SCHEMBL1250865 | 0.74 | CDC7 (0.58) | CDC7DBF4GABRA2GABRB2TSHR | |
| SCHEMBL8036853 | 0.74 | SIRT2 (0.54) | CSF1RGABRA2GABRB2TSHRHSD17B10 | |
| SCHEMBL8022429 | 0.72 | SIRT2 (0.52) | CSF1RGABRA2GABRB2TSHRHSD17B10 | |
| SCHEMBL8762855 | 0.72 | HSD17B10 (0.52) | CSF1RTSHRHSD17B10USP2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831180-B1 | PYRIMIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | BRISTOL MYERS SQUIBB CO (US) | 2015-07-29 | — | — | EP | disclosed |
| US-7589088-B2 | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589088-B2 | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589088-B2 | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-15 | — | — | US | disclosed |
| EP-1831180-A2 | PYRIMIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | Bristol-Myers Squibb Company (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006071762-A2 | PYRIMIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-06 | — | — | WO | disclosed |
| US-20060142576-A1 | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY | 2006-06-29 | — | — | US | disclosed |
| US-20060142576-A1 | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY | 2006-06-29 | — | — | US | disclosed |
| US-20060142576-A1 | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142576-A1 | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | DPP4, DPP9, DPP3 | CSF1R 4104/4885CDC7 1848/4885DBF4 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.